| Literature DB >> 32116986 |
Vincent Huynh1,2, Jan Rosner1,3, Armin Curt1, Spyros Kollias2, Michèle Hubli1, Lars Michels2,4.
Abstract
Background: Spinal cord injury (SCI) and its accompanying changes of brain structure and function have been widely studied and reviewed. Debilitating chronic neuropathic pain (NP) is reported in 53% of SCI patients, and brain changes have been shown to be involved with the presence of this secondary complication. However, there is yet a synthesis of current studies that investigated brain structure, resting connectivity, and metabolite changes that accompanies this condition.Entities:
Keywords: brain plasticity; neuroimaging; neuropathic pain; spinal cord injury; systematic review
Year: 2020 PMID: 32116986 PMCID: PMC7013003 DOI: 10.3389/fneur.2019.01413
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Flow diagrnm of the method followed through the systematic review according to PRISMA standards.
Overview of articles investigating brain alterations in SCI subjects without or with NP included in qualitative synthesis.
| Chen et al. ( | sMRI | 13 | 13 | VAS at MRI acquisition |
| Chen et al. ( | sMRI, rsfMRI | 11 | 11 | VAS at MRI acquisition |
| Jutzeler et al. ( | sMRI | 31 | 28 | EMSCI pain questionnaire, NRS (0–10) |
| Mole et al. ( | sMRI | 18 | 30 | Below-level NP >1 year, NRS (4–10) |
| Yoon et al. ( | sMRI, DTI, PET | 10 | 10 | ISCI basic pain dataset, NRS (0–10) |
| Gustin et al. ( | DTI | 45 | 23 | IASP assessment, NRS (0–10) |
| Min et al. ( | rsfMRI | 18 | 18 | VAS (0–100) at MRI acquisition |
| Widerström-Noga et al. ( | MRS | 24 | 54 | MPI-SCI, NRS (0–10), pain diary |
| Gustin et al. ( | MRS | 21 | 22 | IASP SCI pain taxonomy, VAS (0–10) |
| Widerström-Noga et al. ( | MRS | 24 | 68 | MPI-SCI, NRS (4–10) |
| Stanwell et al. ( | MRS | 10 | 10 | Pain interview and assessment |
| Pattany et al. ( | MRS | 10 | 16 | Pain interview, drawings, NRS (0–10) |
Summary of articles included in qualitative synthesis. Details include neuroimaging modality, number of SCI subjects with or without NP, number of healthy controls, and NP characterization used to differentiate or characterize SCI subjects. Ranges from 0 to 10 or 0 to 100 are commonly used to depict “no pain” to “worst pain imaginable” for NRS and VAS.
DTI, diffusion tensor imaging; EMSCI, European Multicenter Study about Spinal Cord Injury; HC, healthy controls; IASP, International Association for the Study of Pain; ISCI, International Spinal Cord Injury; ISCIP, International Spinal Cord Injury Pain Classification; MPI, multidimensional pain inventory; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NP, neuropathic pain; NRS, numerical rating scale; PET, positron emission tomography; rsfMRI, resting-state functional MRI; SCI, spinal cord injury; sMRI, structural MRI; VAS, Visual Analog Scale.
Study also included task-based fMRI results omitted in qualitative synthesis.
Study did not identify whether pain was nociceptive or neuropathic.
Demographics of SCI subgroups included in the study.
| Chen et al. ( | SCI-NP | 0 | – | – | – | – | – | – |
| SCI-no NP | 13 | 51.3 ± 6.4 | 10/3 | C3–C8 | 2B, 2C, 9D | 11.7 ± 15.3 d | 0 | |
| Chen et al. ( | SCI-NP | 0 | – | – | – | – | – | – |
| SCI-no NP | 11 | 50 ± 4.9 | 9/2 | C3–C8 | 1B, 2C, 8D | 10.0 ± 7.9 d | 0 | |
| Jutzeler et al. ( | SCI-NP | 13 | 46.9 ± 11.4 | 11/2 | C2–L3 | 5A, 2B, 6D | 12.8 + 8.4 yrs | 4.0 ± 2.1 |
| SCI-no NP | 15 | 45.9 ± 12.8 | 15/0 | C4–T12 | 6A, 3B, 2C, 4D | 12.2 ± 7.7 yrs | 0 | |
| Mole et al. ( | SCI-NP | 18 | 51.3 ± 7.9 | n/a | C5–T5 | n/a | 11.1 ± 8.5 yrs | 6.0 ± 1.6 |
| SCI-no NP | 12 | 54.3 + 16.9 | n/a | C5-T5 | n/a | 17.7 ± 11.4 yrs | 0 | |
| Yoon et al. ( | SCI-NP | 10 | 39.8 ± 6.1 | 7/3 | C4–T11 | 7A, 3B | 18.4 ± 6.1 mths | 7.6 ± 0.5 |
| SCI-no NP | 0 | – | – | – | – | – | – | |
| Gustin et al. ( | SCI-NP | 12 | 48.0 ± 4.0 | n/a | C8–T10 | 12A | 16.0 ± 5 yrs | 4.3 ± 0.4 |
| SCI-no NP | 11 | 38.0 ± 3.0 | n/a | T3–T10 | 11A | 13 ± 2 yrs | 0 | |
| Min et al. ( | SCI-NP | 18 | 57.7 ± 11.9 | 12/6 | C2–C7 | 5C, 13D | 49.8 ± 33.7 wks | 46.6 ± 23.3 |
| SCI-no NP | 0 | – | – | – | – | – | – | |
| Widerström-Noga et al. ( | SCI-NP | |||||||
| SCI-HNP | 19 | 43.0 ± 12.5 | 16/3 | n/a | 6A, 13B–D | 12.0 ± 9.7 yrs | 6.4 ± 1.6 | |
| SCI-LNP | 35 | 35.7 ± 12.4 | 28/7 | n/a | 24A, 11B–D | 13.1 ± 9.7 yrs | 1.6 ± 1.5 | |
| SCI-no NP | 0 | – | – | – | – | – | – | |
| Gustin et al. ( | SCI-NP | 12 | 57.0 ± 4.0 | 8/4 | T3–T12 | 12A | n/a | 3.6 ± 0.8 |
| SCI-no NP | 10 | 50.0 ± 4.0 | 8/2 | T3–T10 | 10A | n/a | 0 | |
| Widerström-Noga et al. ( | SCI-NP | |||||||
| SCI-HNP | 19 | 40.4 ± 11.8 | 14/5 | C–S5 | 9A, 10B–D | 12.0 ± 9.9 yrs | ~4.1 ± 0.8 | |
| SCI-LNP | 31 | 37.5 ± 13.4 | 26/5 | C–S5 | 17A, 14B–D | 10.6 ± 9.1 yrs | ~3.1 ± 1.0 | |
| SCI-no NP | 18 | 36.8 ± 11.0 | 14/4 | C-S5 | 14A, 3B–D | 16.2 ± 9.5 yrs | – | |
| Stanwell et al. ( | SCI-NP | 5 | n/a | n/a | n/a | 5A | 63.6 ± 49.6 mths | n/a |
| SCI-no NP | 5 | n/a | n/a | n/a | 5A | 58.2 ± 59.7 mths | n/a | |
| Pattany et al. ( | SCI-NP | 7 | 46.2 ± 16.2 | 7/0 | C8–L3 | n/a | 7.6 ± 6.3 yrs | 5 < |
| SCI-no NP | 9 | 34.8 ± 10.0 | 9/0 | C4–L3 | n/a | 11.3 ± 9.6 yrs | 0 | |
Summary of demographics for SCI subgroups as described in each study. Study order is based on neuroimaging modality as reported in .
AIS, ASIA Impairment Scale (A, sensorimotor complete; B, motor complete, sensory incomplete; C and D, sensory motor incomplete; E, normal); C, cervical level; d, days; f, female; L, lumbar level; LOI, level of injury; m, male; mths, months; n/a, not available; NP, neuropathic pain; S, sacral level; SCI, spinal cord injury; SCI-HNP, SCI subjects with high NP; SCI-LNP, SCI subjects with low NP; SCI-NP, SCI subjects with NP; SCI-no NP, SCI subjects without NP; T, thoracic level; TSI, time since injury; wks, weeks; yrs, years.
Traumatic SCI.
Standard error of mean.
Unspecified information.
~Multidimensional pain inventory—SCI version subscale: pain severity.
Study did not identify whether pain was nociceptive or neuropathic.
Mean and standard deviation of whole SCI cohort.
Neuroimaging studies investigating NP within the SCI cohort.
| Jutzeler et al. ( | sMRI | Whole brain; | SCI-NP vs. SCI-no NP: | |
| Mole et al. ( | sMRI | Whole brain: | SCI-NP vs. SCI-no NP: | |
| Min et al. ( | rsfMRI | Bilateral M1, | SCI-pain vs. SCI-no pain: n/a | |
| Yoon et al. ( | sMRI | Whole | sMRI and PET: | SCI-NP vs. SCI-no NP: n/a |
| Gustin et al. ( | DTI | Whole | SCI-NP vs. SCI-no NP: | |
| Widerström- Noga et al. ( | MRS | Thalamus | Independent | SCI-NP high pain vs. low pain:↓ NAA/Ins and Glx/Ins |
| Gustin et al. ( | MRS | Thalamus | Independent | SCI NP vs. SCI no NP:NAA/Cr and GABA/Cr |
| Widerström-Noga et al. ( | MRS | ACC | Independent | SCI-NP high pain vs. low pain:Ins, Cr and Cho ↓ NAA/Ins and Glx/Ins |
| Stanwell et al. ( | MRS | Thalamus, PFC, ACC | Wavelet-based significant testing | SCI-NP vs. SCI-no NP: |
| Pattany et al. ( | MRS | Thalamus | Post hoc | SCI-NP vs. SCI-no NP: |
Results of studies investigating differences between SCI-NP and SCI-no NP subjects unless stated otherwise. Study order is based on neuroimaging modality as reported in .
↔ No significant changes; ↑ significant increase; ↓ significant decrease.
Neuroimaging studies investigating SCI subjects with NP compared to healthy controls.
| Jutzeler et al. ( | sMRI | Whole brain; | SCI-NP vs. controls: | ||
| Mole et al. ( | sMRI | Whole brain: | SCI-NP vs. controls: | ||
| Min et al. ( | rsfMRI | M1, SMA, S1, S2, BG, dlPM, vlPM | SCI-pain vs. controls: | ||
| Yoon et al. ( | sMRI | Whole brain | sMRI and PET: | SCI-NP vs. controls: | |
| Gustin et al. ( | DTI | Whole brain | SCI-NP vs. controls: | ||
| Widerström- Noga et al. ( | MRS | Thalamus | Independent | SCI-NP high pain vs. controls: | |
| Gustin et al. ( | MRS | Thalamus | Independent | SCI-NP vs. controls: | |
| Widerström-Noga et al. ( | MRS | ACC | Independent | SCI -NP high pain vs. controls: | |
| Stanwell et al. ( | MRS | Thalamus, | Wavelet-based significant testing | SCI-NP vs. controls: n/a | |
| Pattany et al. ( | MRS | Thalamus | Post hoc | SCI-NP vs. controls: | |
Results of studies investigating differences between SCI-NP subjects and healthy controls unless stated otherwise. Study order is based on neuroimaging modality as reported in .
ACC, anterior cingulate cortex; BG, basal ganglia; CC, corpus callosum; Cr, creatine; CST, corticospinal tract; DTI, diffusion tensor imaging; dlPM, dorsolateral premotor cortex; FA, fractional anisotropy; FC, functional connectivity; FDR, false-discovery rate; FWE, family-wise error; GABA, gamma (γ)-aminobutyric acid; Glx, glutamate and glutamine; GMV, gray matter volume; Ins, myo-inositol; k, minimum cluster size; L, Left; M1, motor cortex; MD, mean diffusivity; mFG, medial frontal gyrus; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; PET, positron emission tomography; PFC, prefrontal cortex; PMC, premotor cortex; PPC, posterior parietal cortex; R, right; rsfMRI, resting-state fMRI; S1, somatosensory cortex 1; S2, somatosensory cortex 2; SCI, spinal cord injury; SLF, superior longitudinal fasciculus; SMA, supplementary motor area; sMRI, structural MRI; SCI NP, SCI subjects with NP; SCI no NP, SCI subjects without NP; SVC, small volume correction; TFCE, threshold-free cluster enhancement; vlPM, ventrolateral premotor cortex; WMV, white matter volume.
↔ No significant changes; ↑ significant increase; ↓ significant decrease.
Neuroimaging studies investigating SCI subjects without NP compared to healthy controls.
| Chen et al. ( | sMRI | Whole brain; S1, M1 and thalamus as region of interests | SCI-no pain vs. controls: | |
| Chen et al. ( | sMRI rsfMRI | Whole brain | sMRI: | SCI-no pain vs. controls:↓ GMV in L hippocampus, L parahippocampal gyrus, R superior and middle frontal gyrus↔ WMV↓ ALFF in L OFC↓ intranetwork FC in L middle occipital gyrus |
| Jutzeler et al. ( | sMRI | Whole brain; M1, S1, S2, PMC, insula, thalamus, and ACC as regions of interests | SCI-no NP vs. controls:↓ GMV in ACC and M1 | |
| Mole et al. ( | sMRI | Whole brain:M1, S1, thalamus, | SCI-no NP vs. controls: | |
| Gustin et al. ( | DTI | Whole brain | SCI-no NP vs. controls: | |
| Gustin et al. ( | MRS | Thalamus | Independent | SCI-no NP vs. controls: |
| Widerström-Noga et al. ( | MRS | ACC | Independent | SCI-no NP vs. controls: |
| Stanwell et al. ( | MRS | Thalamus, PFC, and ACC | Wavelet-based significant testing | SCI-no NP vs. controls: n/a |
| Pattany et al. ( | MRS | Thalamus | Post hoc | SCI-no NP vs. controls:↔ NAA↑ NAA/Ins↓ Ins |
Results of studies investigating differences between SCI-no NP subjects and healthy controls unless stated otherwise. Study order is based on neuroimaging modality as reported in .
ACC, anterior cingulate cortex; ALFF, amplitude of low-frequency fluctuations; DTI, diffusion tensor imaging; FA, fractional anisotropy; FWE, family-wise error; GMV, gray matter volume; Ins, myo-inositol; k, minimum cluster size; L, left; M1, motor cortex; MD, mean diffusivity; mFG, medial frontal gyrus; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; PFC, prefrontal cortex; PMC, premotor cortex; PPC, posterior parietal cortex; R, right; rsfMRI, resting-state fMRI; S1, somatosensory cortex 1; S2, somatosensory cortex 2; SCI, spinal cord injury; sMRI, structural MRI; NP, neuropathic pain; SCI NP, SCI subjects with NP; SCI no NP, SCI subjects without NP; WMV, white matter volume.
↔ No significant changes; ↑ significant increase; ↓ significant decrease.
Figure 2Schematic overview of neuroimaging studies reporting brain differences in SCI subjects with NP compared to SCI subjects without NP. Red brain areas indicate region reported to be affected in articles included in the qualitative synthesis. Labeled boxes describe the type of alteration reported in the brain region. ACC, Anterior Cingulate Cortex; Cr, Creatine; GABA, y-aminobutyric acid; Glx, Glutamate and Glutamine; GMV, Gray Matter Volume; Ins, Myo-inositol; Ml, Prinmy Motor Cortex; MD, Mean Diffusivity; mOFC, Medial Orbitofrontal Cortex; NAA, N-acetyl aspattate; PFC, Prefrontal Cortex; PMC, Premotor Cortex; PPC, Posterior Parietal Cortex; Sl, Primary Somatosensory Cortex; S2, Secondary Somatosensory Cortex; WMV, White Matter Volume. ↓ Significant decrease; ↑ Significant increase.